{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:52:21Z","timestamp":1793976741177,"version":"4.8.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The detection of human epidermal growth factor receptor 2 (HER2) expression status is essential to determining the chemotherapy regimen for breast cancer patients and to improving their prognosis. We developed a deep learning radiomics (DLR) model combining time-frequency domain features of ultrasound (US) video of breast lesions with clinical parameters for predicting HER2 expression status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Data for this research was obtained from 807 breast cancer patients who visited from February 2019 to July 2020. Ultimately, 445 patients were included in the study. Pre-operative breast ultrasound examination videos were collected and split into a training set and a test set. Building a training set of DLR models combining time-frequency domain features and clinical features of ultrasound video of breast lesions based on the training set data to predict HER2 expression status. Test the performance of the model using test set data. The final models integrated with different classifiers are compared, and the best performing model is finally selected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The best diagnostic performance in predicting HER2 expression status is provided by an Extreme Gradient Boosting (XGBoost)-based time-frequency domain feature classifier combined with a logistic regression (LR)-based clinical parameter classifier of clinical parameters combined DLR, particularly with a high specificity of 0.917. The area under the receiver operating characteristic curve (AUC) for the test cohort was 0.810.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study provides a non-invasive imaging biomarker to predict HER2 expression status in breast cancer patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1144812","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T05:43:51Z","timestamp":1681796631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Deep learning radiomics model based on breast ultrasound video to predict HER2 expression status"],"prefix":"10.3389","volume":"14","author":[{"given":"Meng-Yao","family":"Quan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Xia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Chong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0051-RA","article-title":"Molecular testing in breast cancer a guide to current practices","volume":"140","author":"Hagemann","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.2470152","article-title":"Studies of the her-2\/Neu proto-oncogene in human-breast and ovarian-cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21634","article-title":"Evolving standards of care and new challenges in the management of HER2-positive breast cancer","volume":"70","author":"Choong","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B6","article-title":"Trastuzumab plus adjuvant chemotherapy improves survival of operable HER-2 positive breast cancer","volume":"6","author":"Nanyan","year":"2006","journal-title":"J Evidence-Based Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102384","article-title":"Validity and utility of HER2\/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review","volume":"106","author":"Verschoor","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical Oncology\/College of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2013improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ajcp\/aqz010","article-title":"Pathologic features and clinical implications of breast cancer with HER2 intratumoral genetic heterogeneity","volume":"152","author":"Muller","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1309\/ajcpxtzskbrip07w","article-title":"Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity","volume":"136","author":"Allison","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.10.025","article-title":"Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature","volume":"43","author":"Meattini","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0635-5","article-title":"Reliability of receptor assessment on core needle biopsy in breast cancer patients","volume":"34","author":"Seferina","year":"2013","journal-title":"Tumor Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01630","article-title":"Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients","volume":"101","author":"Tamaki","year":"2010","journal-title":"Cancer Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv611","article-title":"Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry","volume":"27","author":"Niikura","year":"2016","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1309\/ajcp51hcgpopwscy","article-title":"Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab","volume":"144","author":"Lee","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4453-8","article-title":"HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma","volume":"166","author":"Hou","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.47162\/rjme.62.1.28","article-title":"Analysis of breast cancer subtypes and their correlations with receptors and ultrasound","volume":"62","author":"Sechel","year":"2021","journal-title":"Rom J Morphol Embryol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clinimag.2021.03.039","article-title":"Molecular markers, pathology, and ultrasound features of invasive breast cancer","volume":"79","author":"Huang","year":"2021","journal-title":"Clin Imaging."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10225394","article-title":"Is there a correlation between multiparametric assessment in ultrasound and intrinsic subtype of breast cancer","volume":"10","author":"Gumowska","year":"2021","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.04.002","article-title":"Radiomics in breast cancer classification and prediction","volume":"72","author":"Conti","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B24","first-page":"E586","article-title":"Introduction to radiomics","volume":"45","author":"Court","year":"2018","journal-title":"Med Phys"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316204","article-title":"Deep learning radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis b: a prospective multicentre study","volume":"68","author":"Wang","year":"2019","journal-title":"Gut."},{"key":"B26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1145\/3065386","article-title":"ImageNet classification with deep convolutional neural networks","volume":"60","author":"Krizhevsky","year":"2017","journal-title":"Commun ACM."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11831-022-09738-3","article-title":"A systematic literature review of breast cancer diagnosis using machine intelligence techniques","volume":"29","author":"Nemade","year":"2022","journal-title":"Arch Comput Methods Eng"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.829041","article-title":"Predicting HER2 status in breast cancer on ultrasound images using deep learning method","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.media.2022.102490","article-title":"Extracting keyframes of breast ultrasound video using deep reinforcement learning","volume":"80","author":"Huang","year":"2022","journal-title":"Med Image Anal"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.inffus.2017.10.005","article-title":"Fusing texture, shape and deep model-learned information at decision level for automated classification of lung nodules on chest CT","volume":"42","author":"Xie","year":"2018","journal-title":"Inf Fusion."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/srep11085","article-title":"Identifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decision","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13244-020-00887-2","article-title":"Radiomics in medical imaging-\"how-to\" guide and critical reflection","volume":"11","author":"van Timmeren","year":"2020","journal-title":"Insights Imaging."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2020.105823","article-title":"YOLO based breast masses detection and classification in full-field digital mammograms","volume":"200","author":"Aly","year":"2021","journal-title":"Comput Methods Programs Biomed"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2020.105584","article-title":"Evaluation of deep learning detection and classification towards computer-aided diagnosis of breast lesions in digital X-ray mammograms","volume":"196","author":"Al-Antari","year":"2020","journal-title":"Comput Methods Programs Biomed"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1109\/tnnls.2018.2861838","article-title":"Dynamic collaborative tracking","volume":"30","author":"Zhu","year":"2019","journal-title":"IEEE Trans Neural Netw Learn Syst"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25186","article-title":"Clinical practice patterns and cost-effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients","volume":"116","author":"Fitzgibbons","year":"2010","journal-title":"Cancer."},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","article-title":"Phase I study of Ga-68-HER2-Nanobody for PET\/CT assessment of HER2 expression in breast carcinoma","volume":"57","author":"Keyaerts","year":"2016","journal-title":"J Nucl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00569","article-title":"Development of a Tc-99m-Labeled single-domain antibody for SPECT\/CT assessment of HER2 expression in breast cancer","volume":"18","author":"Zhao","year":"2021","journal-title":"Mol Pharm"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-021-01688-3","article-title":"Prediction of HER2 expression in breast cancer by combining PET\/CT radiomic analysis and machine learning","volume":"36","author":"Chen","year":"2022","journal-title":"Ann Nucl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122264","article-title":"Polyp detection from colorectum images by using attentive YOLOv5","volume":"11","author":"Wan","year":"2021","journal-title":"Diagnostics (Basel)."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188864","article-title":"Clinical applications of deep learning in breast MRI","volume":"1878","author":"Zhao","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-Low-Expressing advanced breast cancer: Results from a phase ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/1878-0261.13021","article-title":"Gene expression profiles of breast cancer metastasis according to organ site","volume":"16","author":"Bras\u00f3-Maristany","year":"2022","journal-title":"Mol Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1144812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T05:43:54Z","timestamp":1681796634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1144812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":44,"alternative-id":["10.3389\/fendo.2023.1144812"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1144812","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"article-number":"1144812"}}